Literature DB >> 15236306

Characterization of rat liver microsomal metabolites of AM-630, a potent cannabinoid receptor antagonist, by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.

Qiang Zhang1, Peng Ma, Weiqun Wang, Richard B Cole, Guangdi Wang.   

Abstract

The in vitro metabolism of AM-630 was studied by high-performance liquid chromatography coupled with tandem mass spectrometry. AM-630 is an aminoalkylindole analogue that behaves primarily as a potent CB2-selective antagonist. In this study, 17 metabolic products were identified that resulted from the incubation of AM-630 in rat liver microsome preparations. Six metabolic pathways were proposed to account for all detected metabolites: (1) o-demethylation of the methoxyphenyl group, (2) morpholinyl ring opening, (3) hydroxylation on the methoxy/hydroxyl phenyl ring, (4) hydroxylation on the indole ring, (5) hydroxylation on the morpholine ring and (6) loss of the morpholine ring leading to metabolites containing either a hydroxylated or a carboxylated alkyl terminal. Three metabolites were identified as morpholinyl ring-opening products: M1, M6 and M13. Six metabolites (M2-M5, M7 and M8) were proposed to be the products of o-demethylation, hydroxylation on the methoxyphenyl group or the morpholinyl ring, dehydration following morpholinyl ring monohydroxylation, or a combination of the above metabolic pathways. The remaining eight metabolites were attributed to a pathway involving the loss of the morpholine ring at various points during the metabolic processes. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236306     DOI: 10.1002/jms.640

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  7 in total

Review 1.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

Review 2.  Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Top Behav Neurosci       Date:  2017

3.  In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB(2)) in rat liver microsomes.

Authors:  Qiang Zhang; Peng Ma; Richard B Cole; Guangdi Wang
Journal:  Eur J Pharm Sci       Date:  2010-06-11       Impact factor: 4.384

Review 4.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

5.  Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist.

Authors:  Jodianne T Wood; Dustin M Smith; David R Janero; Alexander M Zvonok; Alexandros Makriyannis
Journal:  Life Sci       Date:  2012-06-28       Impact factor: 5.037

Review 6.  An Update on the Implications of New Psychoactive Substances in Public Health.

Authors:  Ana Y Simão; Mónica Antunes; Emanuel Cabral; Patrik Oliveira; Luana M Rosendo; Ana Teresa Brinca; Estefânia Alves; Hernâni Marques; Tiago Rosado; Luís A Passarinha; Maristela Andraus; Mário Barroso; Eugenia Gallardo
Journal:  Int J Environ Res Public Health       Date:  2022-04-17       Impact factor: 4.614

7.  Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

Authors:  B P Nutley; N F Smith; A Hayes; L R Kelland; L Brunton; B T Golding; G C M Smith; N M B Martin; P Workman; F I Raynaud
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.